GRI Bio (GRI) vs 60 Degrees Pharmaceuticals (SXTP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GRI Bio is the larger company by market cap ($3.8 million vs $3.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRI | SXTP |
|---|---|---|
| Share price | $1.74 | $0.9654 |
| Market cap | $3.80M | $3.40M |
| 1-day change | +3.57% | -0.73% |
| EPS (TTM) | $-15.32 | $-5.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $64.12 | $8.62 |
| 52-week low | $1.36 | $0.84 |
| Distance from 52-week high | -97.29% | -88.80% |
| Analyst consensus | none | none |
| Avg. price target upside | +963.22% | +283.26% |
| Average volume | 328.24K | 132.31K |
| Shares outstanding | 2.19M | 3.52M |
| Employees | 3 | 3 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About 60 Degrees Pharmaceuticals
SXTP stock →60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
GRI vs SXTP FAQ
Which is bigger, GRI Bio or 60 Degrees Pharmaceuticals?
GRI Bio (GRI) is larger, with a market capitalization of $3.80M compared with $3.40M for 60 Degrees Pharmaceuticals (SXTP).
Are GRI Bio and 60 Degrees Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.